AlphaCentric Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.92M Buy
11,866
+472
+4% +$78.7K 1.7% 7
2026
Q2
$2.16M Buy
11,394
+162
+1% +$30.5K 1.83% 4
2026
Q1
$2.22M Buy
11,232
+610
+6% +$118K 2.21% 4
2025
Q4
$1.95M Buy
+10,622
New +$1.86M 1.95% 6
2024
Q4
$2.08M Buy
+15,843
New +$2.22M 2.07% 8

Other funds holding AZN

AlphaCentric Advisors's AZN Position: Q3 2026 in Review

AlphaCentric Advisors increased its AstraZeneca (AZN) stake by 4.1% in Q3 2026, buying an estimated $78.7K and bringing the position to 11,866 shares worth $1.92M. The position accounts for 1.7% of the portfolio, ranked #7.

AlphaCentric Advisors first reported a position in AZN in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.22M in Q1 2026. 1,406 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • AlphaCentric Advisors held 11,866 shares of AstraZeneca worth $1.92M as of Q3 2026.
  • AlphaCentric Advisors bought 472 AstraZeneca shares in Q3 2026, an estimated $78.7K.
  • AstraZeneca made up 1.7% of AlphaCentric Advisors's portfolio in Q3 2026, its #7 holding.
  • AlphaCentric Advisors first reported a position in AstraZeneca in Q4 2024 and has held it in 5 quarters since.
  • AlphaCentric Advisors's AstraZeneca position peaked at $2.22M in Q1 2026.
  • 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.